By the time the drug was approved, the company might have as little as half the original seventeen years of patent life usually guaranteed to innovators. (bookbrowse.com)
Panelist, «Employing Strategies to Avoid Findings of Obviousness: Legal Analysis and Practical Applications for Brand Names and Generics,» Maximizing Pharmaceutical Patent Life Cycles, American Conference Institute, October 10, 2012 (quinnemanuel.com)
«Eye On The CAFC And District Courts: New Trends, Challenges And Developments In ANDA / Paragraph IV Litigation,» 8th Annual ACI Conference, Maximizing Pharmaceutical Patent Life Cycles, Oct. 24 - 25, 2007 (quinnemanuel.com)